$ 1,050.0
Quantity: 50 MG
Available on backorder
Description
Product name: NNZ 2591
Catalog#: 1808241
Synonyms: Cyclo-L-glycyl-L-2-allylproline,
Sequence: c(Gly- L-2-allylproline)
Modifications: head-to-tail lactam,
CAS NO.:
M.W: C10H14N2O2
M.F.: 194.23
Purity: 95% by HPLC
Format: White powder
Description: Naturally occurring diketopiperazines can be derived from neurotrophic factors and have been reported to be neuroprotective and to improve long-term function. Cyclo-L-glycyl-L-2-allylproline (NNZ-2591) is a modified diketopiperazine based on the endogenous diketopiperazine cyclo-glycyl-proline (cyclic GP). Both cyclic GP and NNZ-2591 have been shown to be neuroprotective after hypoxic-ischaemic (HI) brain injury in rats. NNZ-2591 crosses the blood–brain barrier independent of HI brain injury and remains detectable in the cerebrospinal fluid (CSF) several hours after a single administration. Peripheral administration of NNZ-2591 improves long-term somatosensory-motor function after HI injury in rats. Prevention of both initial and progressive neuronal loss has been suggested as the mechanism underlying its long-term neuroprotection.
Compound ID:
Usage: For Scientific Research Use Only, Not for Human Use.
